You are here: Home » Companies » Q&A
Hindustan Motors to sell 'Contessa' brand to SG Corporate Mobility
Gulf airlines edge past Air India again as post-Covid flying picks up
Business Standard

Gland Pharma rides high on valuation comfort, strong growth prospects

Target prices post brokerage upgrades point to more upsides

Topics
Gland Pharma | US market | growth

Ram Prasad Sahu  |  Mumbai 



Gland Pharma
The company has been facing syringe shortage in the US market and is looking for alternatives even as it incurs higher freight costs for procuring syringes.

The stock of generic injectables major is down 23 per cent since its highs in April this year. The stock has been under pressure on worries of gross margin pressures, component shortages and possibility of an equity stake sale by earlier promoters.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, June 21 2022. 19:06 IST

RECOMMENDED FOR YOU

.